Ultimovacs AS was established in 2011, based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital, Norway. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. Additionally, Ultimovacs will pursue the development of a new first-in-class cancer vaccine solution utilizing the acquired TET-platform which originates from Uppsala University, Sweden.
- Bli medlem
- Om SwedenBIO